Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
- ODYSSEY OUTCOMES Committees and Investigators
- University of Colorado Anschutz Medical Campus
- SUNY Downstate Health Sciences University
- University of Alabama at Birmingham
- Instituto Cardiovascular Rosario (ICR)
- University of Alberta
- University of Toronto
- Leiden University
- Interuniversity Cardiology Institute of the Netherlands
- Charité – Universitätsmedizin Berlin
- Universidad de Santander
- Regeneron Pharmaceuticals, Inc.
- Sanofi-Aventis
- KU Leuven
- Auckland District Health Board
- Université Paris Cité
- Royal Brompton and Harefield NHS Foundation Trust
Research output: Contribution to journal › Article › peer-review
117
Scopus
citations